Please login to the form below

Not currently logged in

Juno boosts CAR-T presence with $80m German acquisition

Stage Cell Therapeutics will contribute in process development and manufacturing

juno therapeutics logo 

Juno Therapeutics has laid claim to another piece of the immuno-oncology territory by buying Germany's Stage Cell Therapeutics in a cash-and-share deal valued at around $80m.

The US company is one of several companies vying to develop a new treatments for cancer based on CAR-T (chimeric antigen receptor T-cell) therapy and - rather than adding new product candidates - Stage Cell adds to its capabilities in process development and manufacturing.

Juno said the deal provides a technology platform that will help it isolate, activate and manufacture cell therapies, and will also reduce the long-term costs associated with producing them. 

The CAR-T approach involves taking T cells from a patient, engineering them to recognise and hone in on cancer surface proteins and then re-infusing them as an anti-tumour therapy. 

Companies developing CAR-Ts are among the hottest stocks in the biotech field at the moment, riding on a wave of interest in immuno-oncology that has already seen new checkpoint inhibitor therapies such as such as Bristol-Myers Squibb's Opdivo (nivolumab) and Merck & Co's Keytruda (pembrolizumab) reach the market.

The promise of the technology lies in its broad applicability across multiple cancer types and that has sparked a flurry of M&A and licensing activity in the CAR-T space, with Merck Serono forging a  $941m alliance with Intrexon in March, Amgen signing a $1bn deal with Kite Pharma in January and Johnson & Johnson (J&J) paying up to $625m for rights to MacroGenics' MGD011 candidate towards the end of 2014.

Stage Cell's platform - known as Streptamer - can be used to make the CAR-T production process more efficient and will help Juno achieve its objective of setting up commercial-scale manufacturing for its lead candidate JCAR015, in trials for acute lymphoblastic leukaemia (ALL).

At the American Association for Cancer Research (AACR) conference earlier this year JCAR015 demonstrated a 91% complete remission rate (CRR) in 22 evaluable relapsed or refractory paediatric ALL patients.

Streptamer will also be applicable to Juno's other main technology platform, the development of T cell receptor  (TCR) technology for modifying T cells so they recognise antigens both on the surface and within the tumour cell.

"This important acquisition is driven by our strategy to have best-in-class process development and manufacturing capabilities," said Juno chief executive Hans Bishop. The company recently started the ball rolling on its manufacturing scale-up with the leasing of a facility near Seattle in Washington.

Novartis is currently leading the CAR-T field with its CTL019 candidate which is in phase II for ALL but reported slightly disappointing data in a phase I mesothelioma study at AACR.

Article by
Phil Taylor

13th May 2015

From: Sales



Featured jobs

Subscribe to our email news alerts


Add my company

Accession was a born from a passion and a vision. A passion to harness the power of market access to...

Latest intelligence

Marketing to healthcare professionals – what’s the key ingredient missing from most campaigns?
What do you think is the difference between a campaign developed to win a share-of-mind with consumers and a campaign designed to gain the attention of healthcare professionals?...
What everyone forgets about good organisational change in pharma
Natasha Cowan speaks to Daphne Chung, Head of Organisational Transformation, to learn how she ensures smooth organisational change that takes all stakeholders into account....
Live from Singapore: Oncology in APAC - Evaluating the opportunity for novel therapies
Live webinar: Tuesday 11th December 2018,16:00 SGT / 17:00 JST...